Otsuka Holdings Co., Ltd

Otsuka Holdings is a Japanese multinational company operating in pharmaceuticals, nutraceuticals, and consumer products. Founded in 1964 as a holding company of the Otsuka Group (originally established in 1921), Otsuka is best known for its contributions to neuroscience, oncology, cardiovascular diseases, and nutrition. The company’s unique business model combines prescription medicines with health products, bridging pharmaceutical innovation and nutritional science.

Mission and Vision

Mission: To create new products for better health worldwide through innovative science and creative ideas.
Vision: To be a total healthcare company, contributing to both the treatment of diseases and the promotion of overall wellness.

Products and Services

Pharmaceuticals: Abilify (aripiprazole, for schizophrenia and bipolar disorder), Samsca (tolvaptan), and oncology treatments.
Nutraceuticals & Consumer Health: Pocari Sweat (ion supply drink), Oronamin C (energy drink), and soy-based nutritionals.
Medical Devices & Diagnostics: Supporting therapies for various chronic conditions.
R&D: Focus on mental health, oncology, immunology, and renal diseases.

Growth and Innovation
Otsuka is globally recognized for its psychiatric medication Abilify, which became a blockbuster drug. The company has expanded in oncology and rare diseases, while its nutraceutical arm ensures strong consumer presence, especially in Asia. Otsuka’s dual focus on pharma and consumer health sets it apart from traditional pharmaceutical companies, making it a diversified healthcare leader.

Global Impact
Operating in over 30 countries, Otsuka combines Japanese innovation with global collaboration. Its pharmaceuticals help millions of patients worldwide, while its consumer products like Pocari Sweat are household names across Asia. Otsuka is committed to sustainability, research into rare diseases, and improving mental health treatment access globally.